Data / Form D filings / XenoTherapeutics Corp
XenoTherapeutics Corp: Form D filings
XenoTherapeutics Corp, a biotechnology company in Enfield, NH, filed 3 Form D notices with the SEC between 2019 and 2021. The latest, on April 6, 2021, reports $1.3 million sold of a $8 million offering to 8 investors.
Find out what XenoTherapeutics Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3 Sunset Walk, Enfield, NH, 03748
- Phone
- (207) 263-0226
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1774010
The full lists. Form D filings in New Hampshire: 127 rows, $6.35, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 6, 2021 | New notice | $8,000,000 | $1,325,000 | $6,675,000 | 8 | Mar 30, 2021 | sec.gov |
| Jun 25, 2019 | Amendment | $4,000,000 | $700,095 | $3,299,905 | 5 | May 22, 2019 | sec.gov |
| May 21, 2019 | New notice | $4,000,000 | $0 | $4,000,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Krysta Moulton | Executive Officer, Director | |
| Paul Holzer | Executive Officer, Director | |
| Jon Adkins | Executive Officer, Director |
Every Form D from the week of Apr 5, 2021 · All recent filings in New Hampshire · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what XenoTherapeutics Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.